DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions

Flanders Medical Research Program

Status and phase

Completed

Phase 4

Conditions

Peripheral Vascular Disease

Critical Limb Ischemia

Intermittent Claudication

Treatments

Device: Everflex 200

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT00637741

FMRP-004

Details and patient eligibility

About

The objective of this clinical investigation is to evaluate the long-term (up to 12 months) outcome of the 200 mm long self-expanding nitinol EverFlex (ev3) stent in long femoropopliteal lesions (TASC C & D) Is is the first time that the use of 200 mm long stents will be evaluated in these lesions. It is expected that the outcome of the treatment with this type of long stents will be better as the treatment of identical lesions lengths with multiple shorter stents.

Enrollment

100 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

GENERAL

De novo, restenotic or reoccluded lesion located in the femoropopliteal arteries suitable for stenting
Patient presenting a score from 2 to 5 following Rutherford classification
Patient is willing to comply with specified follow-up evaluations at the specified times
Patient is >18 years old
Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
Prior to enrollment, the guidewire has crossed target lesion
Patient is eligible for treatment with the self-expanding nitinol EverFlex (ev3) stent

ANGIOGRAPHIC

The target lesion is located within the native femoropopliteal artery until maximally 3 cm proximally of the knee joint.
The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation
The target lesion, visually estimated, has a minimal length of 15 cm and can be categorized as either a type C or D lesions according the TASC II guidelines
Target vessel diameter visually estimated is >4mm and <6.5 mm
There is angiographic evidence of at least one-vessel-runoff to the foot

Exclusion criteria

Presence of another stent in the target vessel that was placed during a previous procedure
Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis
Previous by-pass surgery in the same limb
Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
Perforation at the angioplasty site evidenced by extravasation of contrast medium
Patients with known hypersensitivity to nickel-titanium
Patients with uncorrected bleeding disorders
Aneurysm located at the level of the SFA
Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
Life expectancy of less than twelve months
Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis > 30% or ipsilateral iliac treatment conducted after the target lesion procedure
Use of thrombectomy, artherectomy or laser devices during procedure
Any planned surgical intervention/procedure within 30 days of the study procedure
Any patient considered to be hemodynamically unstable at onset of procedure
Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.